Shares of Fulcrum Therapeutics are up 7% at $13.70 afterhours on insider purchase by investor Ra Capital, which bought 1.9M shares of common stock on January 20th in a total transaction size of $25.0M.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $21 from $18 at Piper Sandler
- Fulcrum Therapeutics price target lowered to $26 from $30 at Oppenheimer
- Fulcrum Therapeutics 9.615M share Spot Secondary priced at $13.00
- Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
